22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › APELLIS PHARMACEUTICALS INC. › 2024-2025

APELLIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 256Asset managers, any item
  • 2,139Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 5 items on APELLIS PHARMACEUTICALS INC.’s Form 8-K, filed June 4, 2025: 2 approved · 3 passed (calculated).

Dissent

Significant dissent: 2 directors (32.5%, 22.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025

Explore APELLIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by APELLIS PHARMACEUTICALS INC.

These tallies are APELLIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 4, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

APELLIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: A. Sinclair Dunlop 54,091,088---- 26,037,79523,918,223 68%Passed (calculated)—
Elect Director: Alec Machiels 62,314,110---- 17,814,77423,918,223 78%Passed (calculated)—
Elect Director: Keli Walbert 76,951,740---- 3,177,14423,918,223 96%Passed (calculated)—
The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. 103,876,32654,603116,178 ---- 99.9%Approved—
The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers. 75,901,9204,167,10359,860 --23,918,223 95%Approved—

Source: APELLIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 4, 2025 — read the filing on EDGAR.

How asset managers voted at the APELLIS PHARMACEUTICALS INC. 2024-2025 meeting

256 asset managers disclosed a vote on at least one APELLIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of APELLIS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: A. Sinclair Dunlop

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%WITHHELD
FOR: 54,091,088WITHHELD: 26,037,795
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: A. Sinclair Dunlop

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: A. Sinclair Dunlop”): 54,091,088 for, 26,037,795 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 28,665,899 for, 4,059,757 withheld, 4 abstained, 740 not voted.

FOR
FOR: 28,665,899ABSTAIN: 4WITHHOLD: 4,059,757NOT VOTED: 740
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: A. Sinclair” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,436,5300 41,465For
Fidelity2,671,9460 00For
State Street5,2400 02,161,662Withhold
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco00 0460,713Withhold
Columbia Threadneedle403,9390 00For
AQR00 0287,765Withhold
Hartford237,7060 00For
Victory Capital1,0220 0198,778Withhold
Exchange Place Advisors Trust00 0138,505Withhold
Lincoln Financial00 0104,202Withhold
Jackson National00 082,733Withhold
Northwestern Mutual55,5330 024,155Mixed
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust00 071,139Withhold
SEI00 066,937Withhold
Direxion Shares ETF Trust00 062,474Withhold
Waddell & Reed00 055,497Withhold
Voya00 045,911Withhold
JPMorgan39,8210 00For
ProShares00 039,528Withhold
DWS00 034,127Withhold

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Alec Machiels

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD
FOR: 62,314,110WITHHELD: 17,814,774
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Alec Machiels

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alec Machiels”): 62,314,110 for, 17,814,774 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 29,574,063 for, 3,151,594 withheld, 2 abstained, 740 not voted.

FOR
FOR: 29,574,063ABSTAIN: 2WITHHOLD: 3,151,594NOT VOTED: 740
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Alec Machie” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,437,9960 20For
Fidelity1,741,9240 0930,022Mixed
State Street2,166,8170 085For
BlackRock00 02,038,646Withhold
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial104,2020 00For
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO00 074,050Withhold
First Trust71,1390 00For
SEI65,6700 01,267For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed55,4970 00For
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Elect Director: Keli Walbert

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 76,951,740WITHHELD: 3,177,144
Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Keli Walbert

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Keli Walbert”): 76,951,740 for, 3,177,144 withheld, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 32,517,454 for, 208,205 withheld, 1 abstained, 740 not voted.

FOR
FOR: 32,517,454ABSTAIN: 1WITHHOLD: 208,205NOT VOTED: 740
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders: Keli Walber” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,436,5330 11,465For
Fidelity2,671,9460 00For
State Street2,166,9020 00For
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial00 0104,202Withhold
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust71,1390 00For
SEI65,6700 01,267For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed00 055,497Withhold
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 75,901,920AGAINST: 4,167,103

Prior year: 89.9% for (June 5, 2024 meeting) ▲ 4.9 pts

Details: description as filed, official tally, votes by 256 asset managers

Description as filed by funds: TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”): 75,901,920 for, 4,167,103 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(c) The stockholders of the Company approved the advisory vote on the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 60 asset managers voting on “TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,435,1612,837 00For
Fidelity2,671,9460 00For
State Street2,164,3462,556 00For
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA0482,718 00Against
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial104,2020 00For
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust71,1390 00For
SEI65,6701,267 00For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed55,4970 00For
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Fund voting reports, all 60 managers: 32,230,743 for, 494,181 against, 735 abstained, 740 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 212 asset managers voting on “TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
EcoR1 Capital, LLC11,895,8080 00For
Wellington11,883,3430 00For
Avoro Capital Advisors LLC4,944,5460 00For
State Street3,618,0604,126 00For
BlackRock3,170,0070 00For
Siren, L.L.C.2,237,5110 00For
JENNISON ASSOCIATES LLC2,061,8464,298 00For
GEODE CAPITAL MANAGEMENT, LLC1,955,2020 00For
AQR1,881,5550 00For
SUVRETTA CAPITAL MANAGEMENT, LLC01,835,131 00Against
Deep Track Capital, LP1,503,6300 00For
ORBIMED ADVISORS LLC1,432,3000 00For
Fidelity1,398,2990 00For
CANADA PENSION PLAN INVESTMENT BOARD1,050,7000 00For
Charles Schwab967,7350 00For
BRAIDWELL LP916,8640 00For
Amundi0592,918 00Against
Invesco517,2980 00For
Nuveen0491,498 00Against
Northern Trust481,4230 00For
BALYASNY ASSET MANAGEMENT L.P.318,3960 00For
Man Group plc310,2830 00For
PICTET ASSET MANAGEMENT SA305,2580 00For
MELLON INVESTMENTS Corp292,1980 00For
Camber Capital Management LP250,0000 00For

Institutional-manager reports, all 212 managers: 57,307,415 for, 3,500,933 against, 36,338 abstained, 9,627 not voted, 53,975 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

97% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 244 asset managers

Description as filed by funds: To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named executive officers; and

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 59 asset managers voting on “To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named execu” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
Fidelity00 00--
State Street00 00--
BlackRock00 00--
Prudential/PGIM00 00--
Charles Schwab00 00Not Voted
TIAA00 00--
Invesco00 00--
Columbia Threadneedle00 00--
AQR00 00--
Hartford00 00--
Victory Capital00 00--
Exchange Place Advisors Trust00 00--
Lincoln Financial00 00--
Jackson National00 00--
Northwestern Mutual00 00--
MASTER INVESTMENT PORTFOLIO00 00--
First Trust00 00--
SEI00 00--
Direxion Shares ETF Trust00 00--
Waddell & Reed00 00--
Voya00 00--
JPMorgan00 00--
ProShares00 00--
DWS00 00--

Fund voting reports, all 59 managers: 735 abstained, 740 not voted, 32,720,213 1 year, 1,571 3 year, 1 unknown, 0 2 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 203 asset managers voting on “To hold an advisory vote on the frequency of future advisory votes on the compensation paid to our named execu” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Wellington00 00--
Avoro Capital Advisors LLC00 00--
State Street00 00--
BlackRock00 00--
Siren, L.L.C.00 00--
JENNISON ASSOCIATES LLC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
AQR00 00--
SUVRETTA CAPITAL MANAGEMENT, LLC00 00--
Deep Track Capital, LP00 00--
ORBIMED ADVISORS LLC00 00--
Fidelity00 00--
CANADA PENSION PLAN INVESTMENT BOARD00 00--
Charles Schwab00 00Not Voted
BRAIDWELL LP00 00--
Amundi00 00--
Invesco00 00--
Nuveen00 00--
Northern Trust00 00--
BALYASNY ASSET MANAGEMENT L.P.00 00--
Man Group plc00 00--
PICTET ASSET MANAGEMENT SA00 00--
MELLON INVESTMENTS Corp00 00--
Camber Capital Management LP00 00--
Victory Capital00 00--

Institutional-manager reports, all 203 managers: 96,909 for, 2,549 against, 9,627 not voted, 48,371,530 1 year, 142,947 3 year. Showing the 25 largest; every one is in the interactive database (link above).

The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 103,876,326AGAINST: 54,603

Prior year: 100.0% for (June 5, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 60 asset managers

Description as filed by funds: Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

APELLIS PHARMACEUTICALS INC.’s own tally for this item (“The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 103,876,326 for, 54,603 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(b) The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 60 asset managers below reported 32,723,901 for, 1,023 against, 735 abstained, 740 not voted.

FOR
FOR: 32,723,901AGAINST: 1,023ABSTAIN: 735NOT VOTED: 740
Largest asset managers voting on “Ratification of the appointment of Deloitte & Touche LLP as our independent registered public accounting firm ” at APELLIS PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard20,437,9980 00For
Fidelity2,671,9460 00For
State Street2,166,9020 00For
BlackRock2,038,6460 00For
Prudential/PGIM1,113,7910 00For
Charles Schwab962,5250 00For
TIAA482,7180 00For
Invesco460,7130 00For
Columbia Threadneedle403,9390 00For
AQR287,7650 00For
Hartford237,7060 00For
Victory Capital199,8000 00For
Exchange Place Advisors Trust138,5050 00For
Lincoln Financial104,2020 00For
Jackson National82,7330 00For
Northwestern Mutual79,6880 00For
MASTER INVESTMENT PORTFOLIO74,0500 00For
First Trust71,1390 00For
SEI66,9370 00For
Direxion Shares ETF Trust62,4740 00For
Waddell & Reed55,4970 00For
Voya45,9110 00For
JPMorgan39,8210 00For
ProShares39,5280 00For
DWS34,1270 00For

Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).

Largest APELLIS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,661,000 shares outstanding at the time of that meeting.

Fund voting reports: top APELLIS PHARMACEUTICALS INC. shareholders by shares voted on “TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 16.26%
2Fidelity 2.13%
3State Street 1.72%
4BlackRock 1.62%
5Prudential/PGIM 0.89%
6Charles Schwab 0.77%
7TIAA 0.38%
8Invesco 0.37%
9Columbia Threadneedle 0.32%
10AQR 0.23%
Institutional-manager reports: top APELLIS PHARMACEUTICALS INC. shareholders by shares voted on “TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.”, 2024-2025
#Asset manager % of shares outstanding
1EcoR1 Capital, LLC 9.47%
2Wellington 9.46%
3Avoro Capital Advisors LLC 3.93%
4State Street 2.88%
5BlackRock 2.52%
6Siren, L.L.C. 1.78%
7JENNISON ASSOCIATES LLC 1.64%
8GEODE CAPITAL MANAGEMENT, LLC 1.56%
9AQR 1.50%
10SUVRETTA CAPITAL MANAGEMENT, LLC 1.46%

Reported APELLIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

APELLIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Wellington Management12,303,252 9.79%Form 13F, quarter ended March 31, 2025
Vanguard Group10,130,356 8.06%Form 13F, quarter ended March 31, 2025
Morgan Stanley9,626,123 7.66%Form 13F, quarter ended March 31, 2025
BlackRock6,329,598 5.04%Form 13F, quarter ended March 31, 2025
Deep Track Capital, LP4,532,374 3.61%Schedule 13G, filed May 15, 2026
State Street3,941,405 3.14%Form 13F, quarter ended March 31, 2025
RTW Investments, LP3,685,045 2.93%Schedule 13G, filed May 15, 2026
Geode Capital1,950,046 1.55%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)1,503,209 1.20%Form 13F, quarter ended March 31, 2025
Norges Bank1,007,920 0.80%Form 13F, quarter ended March 31, 2025

Percentages above are of 125,661,000 shares outstanding, as reported by APELLIS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At APELLIS PHARMACEUTICALS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 256 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,139 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO HOLD AN ADVISORY VOTE TO APPROVE THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — APELLIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: APELLIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 4, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APELLIS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

APELLIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).

Cite this page

Proxy Votes Now, “APELLIS PHARMACEUTICALS INC. 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/apellis-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.